Patents Assigned to UNIVERSITÉ CLAUDE BERNARD—LYON
-
Patent number: 11772325Abstract: A method for producing a 3D-printed tissue substitute is disclosed, utilizing a 3D printing device including a tank including a yield stress fluid in which the material is printed, the printing material delivered by the cartridge includes polyvinyl alcohol and gelatin, the method including a step following which, after printing the material in the yield stress fluid, a printed intermediate device is solidified in the yield stress fluid by lowering the temperature of the tank. The intermediate device is removed from the tank, rinsed and dried in order to obtain the tissue substitute.Type: GrantFiled: June 22, 2022Date of Patent: October 3, 2023Assignees: SEGULA ENGINEERING, UNIVERSITE CLAUDE BERNARD—LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Lucas Lemarie, Edwin-Joffrey Courtial
-
Patent number: 11740243Abstract: A non invasive diagnostic method of pancreatic ductal adenocarcinoma (PDAC) in a subject is provided. The method comprises the step of measuring the level of ?ig-h3 protein in a blood sample wherein the serum level of ?ig-h3 is positively correlated with the risk of having a PDAC. By following studies on 2 distinct cohorts of 20 and 104 of PDAC patients, and on PDAC mouse model, the inventors show that ?ig-h3 can be directly detected in the blood sample and ?ig-h3 is expressed very early in tumorigenesis in pancreatic neoplastic lesions. Also provided is a ?ig-h3 protein, for use in the treatment of PDAC. The inventors found that ?ig-h3 bind directly on CD8+ T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing ?ig-h3 antibodies in PDAC mouse model reduced tumor growth by enhancing CD8+ T cell anti-tumoral response.Type: GrantFiled: March 15, 2017Date of Patent: August 29, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ CLAUDE BERNARD—LYON, CENTRE LEON BERARD, KIST (KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY)Inventors: Kim In-San, Philippe Bertolino, Ana Hennino
-
Patent number: 11180556Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.Type: GrantFiled: April 23, 2018Date of Patent: November 23, 2021Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon BerardInventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
-
Patent number: 10745482Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.Type: GrantFiled: August 6, 2019Date of Patent: August 18, 2020Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Jean Paoli & Irene Calmettes, Universite d' Aix-Marseille, Universite Claude Bernard—Lyon 1, Centre Leon BerardInventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
-
Patent number: 10682630Abstract: The invention relates to a composition that contains a first semiconductor SC1, particles that comprise one or more element(s) M in the metal state selected from among an element of groups IVB, VB, VIB, VIIB, VIIIB, IB, IIB, IIIA, IVA and VA of the periodic table, and a second semiconductor SC2 that comprises cerium oxide, with said first semiconductor SC1 being in direct contact with said particles that comprise one or more element(s) M in the metal state, with said particles being in direct contact with said second semiconductor SC2 that comprises cerium oxide in such a way that the second semiconductor SC2 covers at least 50% of the surfaces of the particles that comprise one or more element(s) M in the metal state. The invention also relates to its preparation method as well as its application of photocatalysis.Type: GrantFiled: October 6, 2015Date of Patent: June 16, 2020Assignees: IFP ENERGIES NOUVELLES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE CLAUDE BERNARD—LYON 1Inventors: Dina Lofficial, Antoine Fecant, Denis Uzio, Eric Puzenat, Christophe Geantet
-
Patent number: 10266584Abstract: The present invention relates to antibodies or fragments thereof that specifically bind to glycoprotein (GP) of Ebola virus, and to their use for treating and diagnosing Ebola virus disease.Type: GrantFiled: February 8, 2016Date of Patent: April 23, 2019Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Université Claude Bernard—Lyon 1, ENS—Ecole Normale Superieure de Lyon, Centre National de la Recherche Scientifique (CNRS)Inventors: Olivier Reynard, Viktor Volchkov
-
Patent number: 10266569Abstract: The invention related to isolated peptides including a binding domain of the viral phosphoprotein (P) subunit to the viral RNA free nucleoprotein (N0) which has the property to inhibit the replication of viruses from the subfamily Paramyxovirinae (like Henipavirus, Rubulavirus or Morbillivirus). These isolated peptides may be used for the prevention or the treatment of Paramyxovirinae infection.Type: GrantFiled: July 17, 2015Date of Patent: April 23, 2019Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre National de le Recherche Scientifique (CNRS), Université Claude Bernard—Lyon 1, Ecole Normale Superieure de Lyon (ENS de Lyon), Université Grenobles AlpesInventors: Viktor Volchkov, Marc Jamin, Philip Lawrence, Filip Yabukarski
-
Patent number: 10071108Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.Type: GrantFiled: February 19, 2018Date of Patent: September 11, 2018Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXELInventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
-
Patent number: 9975950Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.Type: GrantFiled: April 20, 2017Date of Patent: May 22, 2018Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon BerardInventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
-
Patent number: 9895380Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.Type: GrantFiled: September 10, 2014Date of Patent: February 20, 2018Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXELInventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
-
Patent number: 9676852Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.Type: GrantFiled: May 26, 2016Date of Patent: June 13, 2017Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon BerardInventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
-
Patent number: 9428500Abstract: The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof, as well as to key intermediates towards their synthesis. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.Type: GrantFiled: May 10, 2013Date of Patent: August 30, 2016Assignees: UNIVERSITA DEGLI STUDI DI MILANO—BICOCCA, UNIVERSITE DE GENEVE, UNIVERSITE CLAUDE BERNARD—LYONInventors: Carlo Gambacorti-Passerini, Luca Mologni, Leonardo Scapozza, William Bisson, Shaheen Ahmed, Peter Goekjian, Sébastien Tardy, Alexandre Orsato, David Gueyrard, Joseph Benoit
-
Patent number: 9023814Abstract: The present invention relates to a calixarene-based glycosylated compound (I) having the formula: (I) wherein D is independently selected in the group comprising a —CH2-group, an oxygen atom, a sulphur atom, a sulfinyl group or a sulfonyl group, E is independently selected in the group comprising a hydrogen, an alkyl having from 1 to 10 carbon atoms, an aryl having from 6 to 20 carbon atoms, a nitrogen dioxide group, an azide group, an amino group, a guanidinium group, a halogen atom, a —CH2 R group wherein R is a hydroxyl, a halogen, an amino group, a N(alkyl)2 group, a NH(alkyl) group, or E represents a —CO—R? wherein R? is a hydrogen atom, a hydroxyl group or an amino, B represents a A-C group wherein A is independently selected in the group comprising an oxygen atom, a sulfur atom, a NH group or a (CH2)i group, i being an integer from 1 to 10, C is independently selected in the group comprising a hydrogen, an alkyl, an alkenyl, an alkynyl, or C is a group of formula (II).Type: GrantFiled: December 10, 2010Date of Patent: May 5, 2015Assignees: Centre National de la Recherche Scientifique, Universite Claude Bernard—Lyon 1, Universite Lille 2—Droit et SanteInventors: Anne Imberty, Sébastien Vidal, Susan Matthews, Karine Faure, Benoit Guery, Samy Cecioni